Trial Profile
A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Alvelestat (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ATALANTa
- 08 Dec 2023 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 Planned End Date changed from 30 Nov 2023 to 1 Dec 2023.
- 23 Oct 2023 Results published in the Mereo BioPharma Media Release